首页> 外国专利> INHIBITION OF VEGF-A SECRETION, ANGIOGENESIS AND/OR NEOANGIOGENESIS BY SINA MEDIATED KNOCKDOWN OF VEGF-C AND RHOA

INHIBITION OF VEGF-A SECRETION, ANGIOGENESIS AND/OR NEOANGIOGENESIS BY SINA MEDIATED KNOCKDOWN OF VEGF-C AND RHOA

机译:通过新浪介导的VEGF-C和RHOA抑制VEGF-A的分泌,血管生成和/或新血管生成

摘要

The invention relates to the use of short interfering nucleic acid molecules (siNAs, such as siRNAs) that modulate the expression of VEGF-C and/or RhoA involved in neovascular angiogenesis. In the present invention, inhibition of VEGF-C and/or RhoA gene expression lead to decreased expression of VEGF-A, which is required for initiation and the sustaining of angiogenesis. Further, the invention also relates to the inhibition of RhoA expression levels along with VEGF-C, so as to derive the benefits of down-regulating two different targets required for angiogenesis. The present invention describes compounds, compositions and methods useful for inhibition of neoangiogenesis. In certain embodiments, the invention relates to methods for inhibiting neovascularization, as well as compounds, such as VEGF-C and RhoA siRNAs, useful in the treatment of ocular disorders such as age related maculardegeneration (AMD), diabetic retinopathy, glaucoma and other neovascular disorders.
机译:本发明涉及调节与新生血管新生有关的VEGF-C和/或RhoA的表达的短干扰核酸分子(siNA,例如siRNA)的用途。在本发明中,VEGF-C和/或RhoA基因表达的抑制导致VEGF-A的表达降低,这是引发和维持血管生成所必需的。此外,本发明还涉及与VEGF-C一起抑制RhoA表达水平,从而获得下调血管生成所需的两个不同靶标的益处。本发明描述了可用于抑制新血管生成的化合物,组合物和方法。在某些实施方案中,本发明涉及用于抑制新血管形成的方法,以及化合物,例如VEGF-C和RhoA siRNA,可用于治疗诸如年龄相关性黄斑变性(AMD),糖尿病性视网膜病,青光眼和其他新血管的眼病疾病。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号